Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Documenti analoghi

• Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?
  di: Sgambato, Assunta, et al.
  Pubblicazione: (2014)
• Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib
  di: Hakozaki, Taiki, et al.
  Pubblicazione: (2019)
• Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?
  di: Dempke, Wolfram C. M., et al.
  Pubblicazione: (2017)
• J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
  di: Gridelli, Cesare, et al.
  Pubblicazione: (2018)
• The adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?
  di: Gridelli, Cesare, et al.
  Pubblicazione: (2020)